We conducted a prospective study of 586 adu lts to determine if associations exis t betwee n fa tigue symptom scores and three classes ofmedications prescribedfor the treatment of chronic rhinosinusitis (CRS): prescription nonsedating antihistamines, topical nasal steroi ds, and antibiotics. Patients were assessed with the ass istance (~f the Rhinosinusitis Symp tom lnventory and Likert-scale fatig ue symptom sco res. On multivariate analysis and correctingfor disease severity, wefo und that significan tly higher fatigue symptom scores were asso ciated with the lise of nonsedating anti hista mines (mea n Like rt sco re: 2.75 vs. 2.27 fo r patients not taking a nonsedating antihistamine; p = 0.029). Higherfatigue scores were also associated with a greater number of antibiotic co urses and more total weeks ofantibiotic lise (p < 0.00 1 in both cases). No association was seen between fatigue scores and the lise of topical nasal steroi ds (mean Like rt score: 2.65 vs. 2.24; p =0.658). We recommend that long -term lise ofa nonsedating ant ihistam ine be scrutini zed in CRS pa tients who report symptoms offa tigue . Uftra STOP"';s m anufactured by U fe5d ence PLUS. Ult raSTOP.... is a trademark o
Introduction
Fatigue is a co mmo n symptom associated with the diagnosis of chro nic rhin osinu sitis (C RS) . In fact , it is one of the criteria used to estab lish a diag nosis of C RS. Chro nic fatigue places a sig nifica nt qu alit y-of-l ife burd en on patients.F and it has attrac ted a significant amount of research effor t because it is associated with many othe r chro nic disease processes, such as infec tio ns, obs truc tive sleep apnea, and chro nic fatig ue sy ndrome itse lf. ' We have often been struck by the frequ ency and deg ree of fatigue symptoms rep orted by our ow n patient s who undergo eva luatio n for CRS. 4 Not infre quent ly, chro nic fatig ue is a significa nt factor that motivates patient s to seek diagnosis and therapy for CRS, The ca use of fatig ue in the CRS sy ndro me co mplex rem ains unknown. Symptoms offatigue may be associated with the pat hoge nes is of CRS itself, wit h the psychological nature of the disease burden in CRS, and/or with the medication regi me n often used to trea t CRS. Many patients cor relate their fatigue with the num ber of antibiotic courses they have taken . Ot her patients co rre late fatig ue with the use of nonsedating antihista mines , and others still wit h the use of topica l nasal steroid sprays, In thi s article, we describe our study of the relationships between fatig ue and medication use in CRS .
Patients and methods
We obtained data at the initial assessme nt of all ad ults who present ed to our instit ution fo r eva luation of CRS. Patien ts were asked to co mplete the Rhinos inusitis Sy mptom Invent ory to arrive at scores for major and mino r CRS sy mptoms.' > Patients were also asked to rate their fatig ue sym ptomatology averaged ove r the previous 12 weeks on a 6-point Likert sca le, rangi ng from 0 (no symptoms of chro nic fatigue) to 5 (severe fatig ue) in the form of an embed ded question . For co ntro l pu rposes, patient s were also asked to rate the severi ty of feve r symptoms on the same 6-po int sca le . Fever is not a major symptom associated wit h chronic rhi nosi nusitis, and therefore it served as a good control co mparato r.
Embedded questions were used to ascertain past and current use of prescription nonsedating antihistamines , topica l nasal steroids, and antibiotics. Antibiotic use was quantified as the num ber of courses and the numb er of week s of ora l antibiotic therapy duri ng the precedin g ca lendar year. Beca use over-the-counter ant ihistamines are we ll know n to cause fatigue, these med ications were excl uded fro m this analysis (this study was co nducted before loratad ine becam e ava ilable as an over-the-co unter preparation, and therefore use of this drug was includ ed The treatment with these appliances covers both intra-capsular and extra-ca psular TMJ treatment. Although some variations of this disorder in the individual patient would lead towards treatment with either primarily the TMJ App liance" or the TMD Appliance!", the use of the two phase system covers the dual complexity in diagnosis whether the problem is just the Joint [intra-capsular] -clicking. pain in the joint or limited opening. or a cranio-mandibular/MPD type disorder lextra-capsularl.
These two categories are often so overlapped that the majority of patients have both intra and extra-capsular symptoms and causes. Figure. Histogram shows the breakdown of fati gue symptom scores 011 the scale ofOto 5. The mean score was 2.5 (±1.5).
Discussion
The reaso n for the presence offatig ue symptoms in the setting of CRS remains an enigma.' The etiology is probably multifactorial, and it may be linked to the disease process of CRS itself, to the side effec ts of medication use, and/or to the psychosocial factors assoc iated with the diagnosis of CRS. Specific associations between chronic fatigue, chronic rhinitis, and CRS have appeared on several occasions in the literature." We pre viou sly identified a significant fraction of patient s who reported moderat e to seve re symptoms of fatigue at the time of evaluation of CRS . 4 Conversely, for patients not taking a topical steroid; p = 0.658). Fatigue did remain significantly associa ted with antihistamine use (mean Likert sco re: 2.75 vs. 2.27 for patients not taking a nonsedating antihistamine; p = 0.029), a grea ter numb er of antibiotic courses (p < 0.00 I), and a greater number of weeks on antibiotics (p < 0.00 I). As expected, the nasal symptom domain score was positively correlated with increasing fatigue symptoms as a marker for increasingly severe symptoms of CRS and appropriately included in the model as a covariate (p < 0.00 I). An interaction term between antihistamine use and steroid use was not statistically significant (p = 0.807, ANaYA).
For the multi variate control comp arison with feve r symptoms, neither nonsedating antihistamines nor topical nasal steroids were assoc iated with fever symptom seve rity (p = 0.309 and p = 0.932, respecti vely). The number of antibiotic co urses did significantly correlate with fever scores (p = 0.00 I).
Results
A total of 586 patients provided co mplete data on symptom scores and medic ation use. The mean age was 40 .3 years.
The mean fatigue score on the sca le of ato 5 was 2.5 (± 1.5) (figure) . Only 16.2% of patients reported no element of chronic fatigue assoc iated with their CRS .
A total of 258 patient s (44.0 %) reporte d that they were taking a nonsedating antihistamine at the time of their evaluation ; on average, antihistamines had been in use for 14.5 wee ks du ring the preced ing 12 month s. Current use of a topical nasal steroid was reported by 346 patients (59.0%) ; the average duration ofuse (off and on) durin g the precedi ng 12 month s was 16.6 week s. The mean numb er of antibiot ic courses prior to eva luation was 2.5 (±2.2), and the mean numb er of weeks on antibiotic therapy was 5.3 (±6.5).
On uni variate analysis, higher fatigue scores were significantly associated with nonsedating antihistamine use (p < 0.00 I ), topic al nasal stero id use (p = 0.002), a greater number of antibiotic courses (p < 0.00 I) , and more total weeks of antibi otic use (p = 0.004) (table). Howev er, in the analysis). Patients were blinded as to the spec ific purpose of this study.
Data on symptoms and medication use were entere d into a Microsoft Exce l spreadshee t and analyzed for accuracy on a case-by-case basis. Data were then imported into SPSS version 10.0 software for statistica l analysis. Standard demographic information with respect to gender, age, symptom sco res, and medication use was com puted. Next, one-way analysis of varia nce (ANaYA) was conducted with fatigue as the dependent variable and medic ation use as the factor variable influencing fatigue. A multivariate ANa YA model was then co nstructed with fatigue sco re as the depend ent variable; current use of a nonsedatin g antihistamine and current use of a topical steroid were independent variabl es;the number of antibiotic courses was entered as a covariate. To control for the probability that increasing disease severity would make multiple medication use more likely (i.e., patient s with more severe CRS are more likely to take both a nonsedating antihistamine and a topical nasal steroid), the combined nasal symptom score domain was also entered as a covariate.The nasal symptom domain sco re is an unweighted average of Likert scores for severity ofsymptoms for nasal obstruc tion, rhinorrhea, and dysosmia. Asecond statistica l model was also run with the numb er of weeks of antibiotic s (rather than the simple number of co urses of antib iotics) as a cova riate . Statistical significance was set at p < 0.05. A similar stat istical analysis was co nducted for fever symptom seve rity as the dependent variable in the multi variate model for purp oses of control co mparison.
Our protocol was approved by our hospital' s committee on clinic al investi gations. CRS . Th is new poli cy shifts the cost bu rden from the thirdparty payer to the patient as an out-of-poc ket expense. In co ntrast, nasa l steroi ds remain prescription medication s, and they are ofte n preferred as first-line agent s for the management of C RS. We have been somewhat co nce rne d abo ut the shift toward non sed atin g ant ihistamin es becau se of their potentia l to crea te or exacerbate fatigue sy mpto ms despi te being classified as " nonsedating. " This shift affec ts patients with CRS becau se before a definitive diagn osis of CRS is made , many such patients are treated according to guide lines for allergic and perennial rhinitis. Further mo re, the impact of such achange in medication reco mmendatio ns may be more significa nt for patient s with CRS in who m fatigu e alrea dy exe rts a sig nificantly negative influen ce on overall qu ality of life. Th ese potential dangers may be additionally compounded in CRS by the fac t that patien ts with C RS ofte n have sy mptoms ye ar-ro und and may therefore be su bject to these fatig ue-re lated side effec ts almos t co nstantly, unl ike seasonal users of non sed ating antihistamines .
Our study es tablishes an assoc iatio n bet ween non sed ating antihistami nes and fatigue sy mpto ms associate d with CRS, but not a causal association. A ca usa l relationship ca n be established only by a prospecti ve, co ntroIIed, random ized trial of non sedating antihis tamines in patient s with CRS. However, we beli eve that our data do provide evidence that it is likely, at least to so me degree, that so me of the fatigue symptoms report ed by patient s with CRS are attri butable to the use of non sed atin g antihistamines. It is also possibl e that a sy nergis tic effe ct exis ts between nonse dating an tihista mines and othe r medi cation s use d to treat CRS , and that the latter may exacerbate the fatig ue- Ches ter repo rted that CRS was Table. Results of the univariate and multivariate statistical analyses more common in patients with chronic fa tig ue than in patients witho ut sy mpto ms of chronic Medication fatigue."
As furthe r ev ide nce of the Nonsedating link between fa tig ue and CRS, antihista mine a quantita tive evaluation of fatig ue sym pto ms is ofte n co n-Topical nas al tained wi thin disease-specific ste roid qu ality-of-l ife outco me measures for CRS, incl udi ng the Rhi nosinusit is Disab ility Index, No. antibiotic the Si no nasal O utcom e Tests, and th e R hin o sinu siti s Out-No. wk on co me Measure . 8 Several studies antibiotics that incorpo rated more globa l health-rel ated qu ality-of-l ife Nasal symptom measures, including the Short domain score Form 36, have also identi fied sig nifica nt eleme nts of fatigue " Fatigue was rated on the Likert scale of 0 (none) to 5 (severe). in patient s with C RSY-IO Nonsedating antihistami nes have long been a main stay of therapy for the treatmen t of perennial rhini tis, allerg ic rhinitis, and C RS . Altho ugh non e of the non sedating antihistam ines ca rries a spec ific Food and Dru g Ad ministration-approved indication fort he treatment ofC RS , they are wide ly used to co ntro l many of the sy mptoms potent iall y associated with CR S. T heir prevalen ce in the treatm ent of CRS is evide nced by the subs tantial frac tion of patients who have alrea dy used a non sedating antihistamine prior to an oto laryngo logic eva luatio n of C RS--44.0% in our study.
Th e introduction of nonse da ting antihistamines represe nted a significa nt adva nce in the treatme nt of many allergic disord ers, including allergic rhinitis and chro nic urt icaria. Th ese an tih istam ines acquire their non sedating pharm acologic profi le throu gh molecul ar mod ification s that limit diffusion across the blood-brain barrier, Th eir lack of ce ntral nervous system effects has been the subject of num erous inves tiga tions, most of which fo und that cog nitive and mo tor skills are not significantly impa ired by these med ications, especially when compa red with first-generati on antihistamines .II However, chro nic fatigue is a much more wides pre ad clinica l syndrome, and cog nitive and motor skill disturba nces represent only tw o com ponents of it.
The cli nica l safety and efficacy of non sed atin g antihistam ines have been we ll estab lished for many sinonasal co nditions. Recentl y, in fac t, loratad ine was deem ed safe enough to be accessed by patients as an over-the-co un ter medication . In our ca tchment area , this pro mp ted ma ny third-p arty payers to adop t over-the -co unter non sed ating antihistamines as a first-line treatm ent for many nasal diagnoses, incl uding rhini tis, allergic rhinitis, and even related side effec ts of the former. Alternatively, it is also poss ible that a pa tie nt's fatigue is linked to an increase in the severity of CRS itself. However, if this were the case, one wo uld also expec t tha t top ical nasal steroids woul d be asso ciated with increasi ng fa tigue scores on multivariate analysis . In fac t, we attempted to co ntro l for increasing disease severity by incl uding the nasal symptom do mai n score in the mult ivari ate analysis, and therefore we believe the associati on bet ween fatigue and the use of non sed ating antihistami nes does exist. Fin all y, the magni tud e of the differen ce in reported fatig ue scores might be see n as small num er icall y. However, previou s studies have determined that on 7-point rating sca les, patient s perceive a difference of appro ximately 0.5 unit s as clinically significa nt.'? Becau se chro nic fatigue has a sig nificant negativ e imp act on qu alit y of life for pati ents wi th CRS , we recommend that they be informed of the potential for additiona l fa tig ue sympto ms before they take a non sed atin g antihistamine. Patient s should also be mon itored for increasin g fa tig ue throu gh out the co urse of therapy.
Because we did not find any assoc iatio n between fatigu e sym ptom s and top ical nasal stero ids , these age nts may be preferable as a first-line thera py for CRS . An oral nonsed atin g antihistamine co uld be added or substi tuted if sym ptoms persist or if side effec ts becom e unaccept abl e. Bu t for now, the optima l medical trea tme nt for patients with newl y diagnosed CR S remains unkn own and warrants continuing investigati on.
